nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.10.2008 | Original Article

Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours

verfasst von: Stephan Good, Martin A. Walter, Beatrice Waser, Xuejuan Wang, Jan Müller-Brand, Martin P. Béhé, Jean-Claude Reubi, Helmut R. Maecke

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Diethylenetriamine-pentaacetic acid (DTPA)-coupled minigastrins are unsuitable for therapeutic application with the available β-emitting radiometals due to low complex stability. Low tumour-to-kidney ratio of the known radiopharmaceuticals is further limiting their potency. We used macrocyclic chelators for coupling to increase complex stability, modified the peptide sequence to enhance radiolytic stability and studied tumour-to-kidney ratio and metabolic stability using ¹¹¹In-labelled derivatives.

Methods

Gastrin derivatives with decreasing numbers of glutamic acids were synthesised using ¹¹¹In as surrogate for therapeutic radiometals for in vitro and in vivo studies. Gastrin receptor affinities of the ^natIn-metallated compounds were determined by receptor autoradiography using ¹²⁵I-CCK as radioligand. Internalisation was evaluated in AR4-2J cells. Enzymatic stability was determined by incubating the ¹¹¹In-labelled peptides in human serum. Biodistribution was performed in AR4-2J-bearing Lewis rats.

Results

IC₅₀ values of the ^natIn-metallated gastrin derivatives vary between 1.2 and 4.8 nmol/L for all methionine-containing derivatives. Replacement of methionine by norleucine, isoleucine, methionine-sulfoxide and methionine-sulfone resulted in significant decrease of receptor affinity (IC₅₀ between 9.9 and 1,195 nmol/L). All cholecystokinin receptor affinities were >100 nmol/L. All ¹¹¹In-labelled radiopeptides showed receptor-specific internalisation. Serum mean-life times varied between 2.0 and 72.6 h, positively correlating with the number of Glu residues. All ¹¹¹In-labelled macrocyclic chelator conjugates showed higher tumour-to-kidney ratios after 24 h (0.37–0.99) compared to ¹¹¹In-DTPA-minigastrin 0 (0.05). Tumour wash out between 4 and 24 h was low. Imaging studies confirmed receptor-specific blocking of the tumour uptake.

Conclusions

Reducing the number of glutamates increased tumour-to-kidney ratio but resulted in lower metabolic stability. The properties of the macrocyclic chelator-bearing derivatives make them potentially suitable for clinical purposes.

Nur mit Berechtigung zugänglich

Wank SA, Pisegna JR, de Weerth A. Cholecystokinin receptor family. Molecular cloning, structure, and functional expression in rat, guinea pig, and human. Ann N Y Acad Sci 1994;713:49–66.PubMedCrossRef

Rehfeld JF. The endoproteolytic maturation of progastrin and procholecystokinin. J Mol Med 2006;84:544–50.PubMedCrossRef

Noble F, Wank SA, Crawley JN, Bradwejn J, Seroogy KB, Hamon M, et al. International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 1999;51:745–81.PubMed

Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389–427.PubMedCrossRef

Reubi JC, Waser B, Laderach U, Stettler C, Friess H, Halter F, et al. Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. Gastroenterology 1997;112:1197–205.PubMedCrossRef

Reubi J, Waser B. Unexpected high incidence of cholecystokinin B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer 1996;67:644–7.PubMedCrossRef

Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997;57:1377–86.PubMed

Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30:781–93.PubMed

Gotthardt M, Behe MP, Beuter D, Battmann A, Bauhofer A, Schurrat T, et al. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2006;33:1273–9.PubMedCrossRef

10.

Gotthardt M, Behe MP, Grass J, Bauhofer A, Rinke A, Schipper ML, et al. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocr Relat Cancer 2006;13:1203–11.PubMedCrossRef

11.

Behr TM, Jenner N, Radetzky S, Behe M, Gratz S, Yucekent S, et al. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 1998;25:424–30.PubMedCrossRef

12.

de Jong M, Bakker W, Bernard B, Valkema R, Kwekkeboom D, Reubi J, et al. Preclinical and initial clinical evaluation of ¹¹¹In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor targeted scintigraphy and radionuclide therapy. J Nucl Med 1999;40:2081–7.PubMed

13.

Behr TM, Jenner N, Behe M, Angerstein C, Gratz S, Raue F, et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 1999;40:1029–44.PubMed

14.

Reubi JC. CCK receptors in human neuroendocrine tumors: clinical implications. Scand J Clin Lab Invest Suppl 2001;234:101–4.PubMed

15.

Kwekkeboom DJ, Bakker WH, Kooij PP, Erion J, Srinivasan A, de Jong M, et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med 2000;27:1312–7.PubMedCrossRef

16.

Reubi JC, Maecke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005;46:67S–75S.PubMed

17.

von Guggenberg E, Behe M, Behr TM, Saurer M, Seppi T, Decristoforo C. ^99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Na-His)acetic acid-modified [d-Glu1]-minigastrin. Bioconjug Chem 2004;15:864–71.CrossRef

18.

Behe M, Becker W, Gotthardt M, Angerstein C, Behr TM. Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur J Nucl Med Mol Imaging 2003;30:1140–6.PubMedCrossRef

19.

Behe M, Behr TM. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers 2002;66:399–418.PubMedCrossRef

20.

Nock BA, Maina T, Behe M, Nikolopoulou A, Gotthardt M, Schmitt JS, et al. CCK-2/Gastrin receptor-targeted tumor imaging with ^99mTc-labeled minigastrin analogs. J Nucl Med 2005;46:1727–36.PubMed

21.

Aloj L, Caraco C, Panico M, Zannetti A, Del Vecchio S, Tesauro D, et al. In vitro and in vivo evaluation of ¹¹¹In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging. J Nucl Med 2004;45:485–94.PubMed

22.

Behr TM, Behe MP. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 2002;32:97–109.PubMedCrossRef

23.

Harrison A, Walker C, Parker D. The in vivo release of ⁹⁰Y from cyclic and acyclic ligand-antibody conjugates. Nucl Med & Biol 1991;18:469–76.

24.

Eisenwiener KP, Powell P, Maecke HR. A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling. Bioorg Med Chem Lett 2000;10:2133–5.PubMedCrossRef

25.

Good S, Maecke H. Kinetics of formation and dissociation of two DOTA-based chelator conjugates with ¹⁷⁷Lu. Eur J Nucl Med Mol Imaging 2003;30(Suppl 2):S319.

26.

Good S, Maecke H. Stability and kinetics of formation of two macrocyclic chelator-conjugates. Nuklearmedizin 2004;43:A11.

27.

Heppeler A, Froidevaux S, Mäcke HR, Jermann E, Béhé M, Powell P, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chemistry A European Journal 1999;5:1016–23.

28.

Eisenwiener KP, Prata MI, Buschmann I, Zhang HW, Santos AC, Wenger S, et al. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [⁶⁷/⁶⁸Ga] and [¹¹¹In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem 2002;13:530–41.PubMedCrossRef

29.

Reubi J, Waser B, Schaer J, Laederach U, Erion J, Srinivasan A, et al. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med 1998;25:481–90.PubMedCrossRef

30.

Reubi JC, Kvols LK, Waser B, Nagorney DM, Heitz PU, Charboneau JW, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990;50:5969–77.PubMed

31.

Christophe J. Pancreatic tumoral cell line AR42J: an amphicrine model. Am J Physiol 1994;266:G963–G71.PubMed

32.

Wild D, Schmitt JS, Ginj M, Maecke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338–47.PubMedCrossRef

33.

Storch D, Behe M, Walter MA, Chen J, Powell P, Mikolajczak R, et al. Evaluation of [^99mTc/EDDA/HYNIC⁰]octreotide derivatives compared with [¹¹¹In-DOTA⁰,Tyr³, Thr⁸]octreotide and [¹¹¹In-DTPA⁰]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med 2005;46:1561–9.PubMed

34.

Maecke H, Good S. Radiometals (non-Tc, non-Re) and bifunctional labeling chemistry. In: Vertes A, Nagy S, Klencsar Z, editors. Handbook of nuclear chemistry. Vol. 4. Netherlands; 2003, p. 279–314.

35.

Bogni A, Bombardieri E, Iwata R, Cadini L, Pascali C. Stability of l-[S-methyl-¹¹C]methionine solutions. J Radioanal Nucl Chem 2003;256:199–203.CrossRef

36.

Liu S, Edwards DS. Stabilization of ⁹⁰Y-labeled DOTA-biomolecule conjugates using gentisic acid and ascorbic acid. Bioconjug Chem 2001;12:554–8.PubMedCrossRef

37.

Good S, Maecke H, Merlo A, Reubi JC. Development of NK-1 receptor mediated radiopharmaceuticals. Nuklearmedizin 2004;43:A7.

38.

Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001;28:1421–9.PubMedCrossRef

39.

Trejtnar F, Laznicek M. Analysis of renal handling of radiopharmaceuticals. Q J Nucl Med 2002;46:181–94.PubMed

40.

de Jong M, Barone R, Krenning E, Bernard B, Melis M, Visser T, et al. Megalin is essential for renal proximal tubule reabsorption of ¹¹¹In-DTPA-octreotide. J Nucl Med 2005;46:1696–700.PubMed

41.

Behe M, Kluge G, Becker W, Gotthardt M, Behr TM. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med 2005;46:1012–5.PubMed

42.

von Guggenberg E, Rupprich M, Virgolini I, Decristoforo C. ^99mTc-HYNIC-Minigastrin: improved in vitro and in vivo properties of a short chain analogue. Eur J Nucl Med Mol Imaging 2005;32(Suppl 1):S35.

43.

Behe M, Reubi JC, Nock B. Evaluation of a DOTA-minigastrin derivative for therapy and diagnosis for CCK-2 receptor positive tumours. Eur J Nucl Med Mol Imaging 2005;32(Suppl 1):S78.

44.

Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998;25:201–12.PubMedCrossRef

Titel: Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours
verfasst von: Stephan Good
Martin A. Walter
Beatrice Waser
Xuejuan Wang
Jan Müller-Brand
Martin P. Béhé
Jean-Claude Reubi
Helmut R. Maecke
Publikationsdatum: 01.10.2008
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2008
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0803-4

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2008

Tetrafluorophenolate of HBED-CC: a versatile conjugation agent for 68Ga-labeled small recombinant antibodies

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors

Concordance between results of somatostatin receptor scintigraphy with 111In-DOTA-DPhe1-Tyr3-octreotide and chromogranin A assay in patients with neuroendocrine tumours

EANM procedure guideline for treatment of refractory metastatic bone pain

188Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomas